Danaher (DHR)
Supplies bioprocessing, life-science, and diagnostic tools with recurring consumables and service.
Something off on this page? Send us feedback.
Sells bioprocessing tools, life-science instruments and consumables, and diagnostic systems to drugmakers, researchers, laboratories, and hospitals. Recurring demand for filters, chromatography resins, reagents, sensors, software, and service follows its installed equipment base, while acquisitions are integrated through the Danaher Business System.
Supplies bioprocessing equipment and consumables, life-science instruments and reagents, and clinical diagnostic systems through Biotechnology, Life Sciences, and Diagnostics. Cytiva and Pall serve biologic-drug development and manufacturing; SCIEX, Leica Microsystems, IDT, Abcam, and Aldevron support research and genomic medicine; Beckman Coulter, Cepheid, Radiometer, Leica Biosystems, and Masimo cover laboratory testing, molecular diagnostics, pathology, pulse oximetry, and patient monitoring.
Applies the Danaher Business System across a decentralized portfolio, using continuous-improvement tools and acquisitions to extend operating-company capabilities. Installed equipment drives recurring sales of filters, chromatography resins, reagents, sensors, software, and services. Most sales come from outside the United States.
Demand depends on biopharma production and capital spending, research funding, hospital testing volumes, and respiratory seasons. Medical-device clearances, reimbursement and procurement policies, and qualified-component supply affect pricing and product launches.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 9, 2026 | UBS | Target | Target: $240 | Target: $250 |
| Jul 22, 2026 | Deutsche Bank | Reiterate | Rating: —Target: $270 | Target: $240 |
| Jul 22, 2026 | RBC Capital | Reiterate | Rating: —Target: $200 | Target: $215 |
| Jul 22, 2026 | Stifel Nicolaus | Target | Target: $260 | Target: $220 |
| Jul 22, 2026 | Guggenheim | Reiterate | Rating: —Target: $275 | Target: $200 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 26, 2026Cash & short-term investments $4.35B · Total debt $26.56B · Total assets $92.37B · Shareholders' equity $52.58B
- Revenue
- $6.27B
- Operating income
- $1.13B
- Net income
- $870.0M
HistoryDividendAnnual yieldUpcoming
| Institutions | 82.92% | 582.89M shares | |
|---|---|---|---|
| 2,183 holders · as of Jun 30, 2026 | |||
| Insiders | 5.52% | 38.78M shares | |
| 24 holders · as of Aug 24, 2026 | |||
| Other | 11.56% | 81.32M shares | |
| remainder | |||
702.99M company shares as of Aug 29, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
BlackRock, Inc.Institution | 7.84% | 55.08M | as of Jun 30, 2026 |
Vanguard Capital Management LLCInstitution | 5.89% | 41.38M | as of Jun 30, 2026 |
Mitchell P. Rales1Insiderdirector, officer: Chairman of Exec. Committee | 5.44% | 40.01M | filed Aug 6, 2026 |
FMR LLCInstitution | 4.20% | 29.54M | as of Jun 30, 2026 |
State Street CorpInstitution | 4.05% | 28.46M | as of Jun 30, 2026 |
- Mitchell P. Rales's transaction reports restate only vehicles that traded; the 2020 ownership statement (40.01M) less the 1.80M net shares sold since is used instead.
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 21, 2026 | Rainer Blair | director, officer: President & CEO | −58,255 | $218.63 |
| May 1, 2026 | Alan G. Spoon | director | −1,358 | $174.67 |
| Feb 19, 2026 | Gregory M. Milosevich | officer: Executive Vice President | −1,320 | $208.01 |
| Nov 25, 2025 | Mitchell P. Rales | director, officer: Chairman of Exec. Committee | −40,625 | $230.38 |
| Nov 18, 2025 | Teri List | director | −3,298 | $226.50 |
- Thermo Fisher Scientific
Full-stack rival across bioprocessing, life-science tools, and diagnostics.
- Agilent Technologies
Head-to-head in analytical instruments, mass spec, genomics, and diagnostics.
- Waters
Dominant HPLC/UPLC and mass spec rival; contests every pharma analytical lab.
- Bio-Rad Laboratories
Overlaps in clinical diagnostics QC, digital PCR, and biopharma process tools.
- Bruker
NMR, mass spec, and microscopy rival; expanding into molecular diagnostics.
- Revvity
Overlaps in genomic screening, immunodiagnostics, and drug-discovery reagents.
- QIAGEN
Molecular dx and sample-prep rival to Cepheid; competes for PCR workflow spend.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Danaher | $221.39 | +2.57% | $151.67B | 38.3 | 25.0 | 6.0 | +5.5% |
| Thermo Fisher Scientific | $659.48 | +0.11% | $244.81B | 35.4 | 25.1 | 5.3 | +10.5% |
| Agilent Technologies | $165.44 | +2.16% | $45.75B | 31.9 | 25.2 | 6.2 | +8.1% |
| Waters | $427.16 | +0.76% | $41.62B | 105.7 | 27.3 | 9.0 | +113.3% |
| Bio-Rad Laboratories | $380.40 | +0.81% | $10.16B | 45.7 | 36.9 | 3.9 | −0.1% |
| Bruker | $61.58 | 0.00% | $9.37B | — | 27.2 | 2.7 | +5.2% |
| Revvity | $143.15 | −0.31% | $16.02B | 68.4 | 25.4 | 5.5 | −1.3% |
| QIAGEN | $43.78 | −2.23% | $9.24B | 23.0 | 17.5 | 4.4 | +0.3% |
| Median | 40.6 | 25.4 | 5.3 | +5.2% |